Search

Deuruxolitinib

[A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

Paliperidone

Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. … It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.

Chromic citrate

XP12B

It was granted Fast Track status for this indication by the FDA in November 2004.

ALMB-0166

It was granted FDA orphan designation in November 2018.[L47067]

Uracil C-13

Uracil C-13 is under investigation in clinical trial NCT01677338 (Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects).

Fenproporex

In 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers. … practice, central nervous system stimulative effects are less notorious than with some other agents such as diethylpropion and mazindol. [7] In the United States fenproporex was never approved by the FDA

Bevacizumab

[A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type … gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically for intravitreal injection, which received European Commission and MHRA marketing authorization in 2024 and FDA

Viltolarsen

[A218186] Hence, viltolarsen is similar to another PMO, [eteplirsen], which gained FDA approval on September 19, 2016; however, [eteplirsen] is specific for exon 51 skipping while viltolarsen is specific … [A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval

Brimonidine

[A178969] The ophthalmic solution of brimonidine was first approved by the FDA in 1996 as Alphagan [label] and brimonidine is the only selective alpha-adrenergic receptor agonist approved for chronic treatment … [A178948] The topical form of brimonidine was approved by the FDA in August 2013 for the symptomatic treatment of persistent facial erythema of rosacea in adults.